OpGen Announces Collaborator in Verification Study for Acuitas® Test
March 13 2018 - 7:30AM
OpGen, Inc. (NASDAQ:OPGN) announced today that it is collaborating
with Beth Israel Deaconess Medical Center (BIDMC) in Boston on a
verification study for OpGen’s Acuitas® AMR Gene Panel u5.47 Assay
and Acuitas Lighthouse® Knowledgebase. The principal
investigator at BIDMC is Stefan Riedel, M.D., Ph.D., D(ABMM), FCAP,
Associate Medical Director of the Clinical Microbiology
Laboratories at BIDMC and Associate Professor of Pathology at
Harvard Medical School. The study plan includes testing
remnant urine specimens from patients at increased risk for
complicated urinary tract infections (cUTI). This prospective
verification study is among the first to evaluate potential
diagnostic and antibiotic decision-making improvements that could
be possible using rapid molecular testing and bioinformatics.
Effective, targeted antimicrobial treatment is of critical
importance in patients with cUTI and other serious infections as
the emergence and spread of antimicrobial-resistant organisms
increase. There are an estimated 400,000 to 800,000 patients each
year in the U.S. with cUTI, and approximately half are at risk for
multidrug-resistant infections. Complicated UTI continues to be a
major cause of hospital admission, morbidity, mortality and excess
health care costs as a growing number of infections are
healthcare-associated in origin.
The Acuitas AMR Gene Panel u5.47 is a new molecular test
developed by OpGen and is currently available for research use
only. The test is designed to detect five key pathogens
semi-quantitatively and 47 antibiotic-resistance genes in under
three hours.
“We are excited to have Beth Israel Deaconess Medical Center as
a collaborator in this important study to evaluate potential
improvements in cUTI management. Our Acuitas AMR Gene Panel u5.47
and Acuitas Lighthouse Knowledgebase are designed to provide
clinically actionable information in under three hours, compared
with legacy microbiology methods that take up to several days. This
collaboration is an important step in verifying our technology’s
performance in clinical research laboratory settings,” said Evan
Jones, Chairman and CEO of OpGen.
About OpGenOpGen, Inc. is harnessing
the power of informatics and genomic analysis to provide complete
solutions for patient, hospital and network-wide infection
treatment and prevention. Learn more at www.opgen.com and
follow OpGen on Twitter and LinkedIn.
OpGen, Acuitas, Acuitas Lighthouse and QuickFISH are
registered trademarks of OpGen, Inc.
Forward-Looking StatementsThis press release
includes statements relating to OpGen’s AMR Gene Panel in
development and its Acuitas Lighthouse Knowledgebase in development
and its commercialization plans for these products. These
statements and other statements regarding OpGen’s future plans and
goals constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to
differ materially from expectations. Factors that could cause our
results to differ materially from those described include, but are
not limited to, our ability to successfully, timely and
cost-effectively develop, seek and obtain regulatory clearance for
and commercialize our product and services offerings, the rate of
adoption of our products and services by hospitals and other
healthcare providers, the success of our commercialization efforts,
the effect on our business of existing and new regulatory
requirements, and other economic and competitive factors. For a
discussion of the most significant risks and uncertainties
associated with OpGen's business, please review our filings with
the Securities and Exchange Commission (SEC). You are cautioned not
to place undue reliance on these forward-looking statements, which
are based on our expectations as of the date of this press release
and speak only as of the date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
OpGen Contact:Michael FarmerSr. Director,
Marketing240-813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Investor Contacts:LHA Investor RelationsKim
Sutton Golodetz212-838-3777kgolodetz@lhai.comorBruce
Voss310-691-7100bvoss@lhai.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Apr 2023 to Apr 2024